Literature DB >> 24878820

Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data.

Roxana Chiorean1, Ioana Berindan-Neagoe2, Cornelia Braicu3, Ioan Stefan Florian4, Daniel Leucuta5, Doinita Crisan6, Valentin Cernea7.   

Abstract

Glioblastoma multiforme (GBM) represents a very aggressive brain tumor. Angiogenesis is the formation of a network of new blood vessels, from preexisting ones. It plays an important role in the formation of the tumor, as it supplies it with oxygen and nutrients. Angiogenesis and inflammation play essential roles in glioblastoma development. These processes are regulated by the balance of a few molecules, acting as pro- or antiangiogenic and pro- or anti-inflammatory factors. The purpose of our study was to evaluate the expression of 7 markers involved in angiogenesis and inflammation pathways in patients with glioblastoma. VEGF, PDGF-bb, IGF-1, TGF-β, TNF-α, IL-6 and IL-8 levels were measured using the ELISA method, in the preoperative sera of 14 patients with histopathologically confirmed glioblastoma multiforme and 32 healthy patients. Serum levels of PDGF-bb, IGF-1 and IL-8 were significantly higher in patients with GBM, compared to the control group (p-value < 0.01). A statistically significant correlation has been found between IGF-1 and IL-6 levels (rho= -0.53, p-value < 0.05) and also between TNF-α and IL-6 levels (rho=0.60, p-value < 0.05). Statistically significant associations have been found between the presence of low levels of IL-8 and the development of coagulation necrosis (p-value < 0.05), high levels of VEGF and development of ischemic necrosis (p-value < 0.01) and high levels of IL-8 and the development of endothelial hyperplasia (p-value < 0.05). We have observed no statistically significant associations between the serum levels of the markers and the survival rates.

Entities:  

Keywords:  ELISA; Glioblastoma multiforme; angiogenesis; histopathology; inflammation; survival rates

Mesh:

Substances:

Year:  2014        PMID: 24878820     DOI: 10.3233/CBM-130310

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  20 in total

1.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

2.  The interplay among psychological distress, the immune system, and brain tumor patient outcomes.

Authors:  Sebastian Otto-Meyer; Jan Lumibao; Eugene Kim; Erik Ladomersky; Lijie Zhai; Kristen L Lauing; Denise M Scholtens; Frank Penedo; Christina Amidei; Rimas V Lukas; Derek A Wainwright
Journal:  Curr Opin Behav Sci       Date:  2019-02-26

Review 3.  Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.

Authors:  Ali Karimi Sisakht; Mohammad Malekan; Farbod Ghobadinezhad; Seyedeh Negar Mousavi Firouzabadi; Ameneh Jafari; Seyed Mohammad Ali Mirazimi; Banafshe Abadi; Rana Shafabakhsh; Hamed Mirzaei
Journal:  Cell Mol Neurobiol       Date:  2022-04-11       Impact factor: 5.046

4.  Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option.

Authors:  Tiziana Annese; Mariella Errede; Michelina De Giorgis; Loredana Lorusso; Roberto Tamma; Domenico Ribatti
Journal:  Methods Mol Biol       Date:  2023

5.  Commentary: Evaluating potential glioma serum biomarkers, with future applications.

Authors:  Michael Goutnik; Brandon Lucke-Wold
Journal:  World J Clin Oncol       Date:  2022-05-24

Review 6.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

7.  Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival.

Authors:  Laurent Muller; Sylvia Muller-Haegele; Masato Mitsuhashi; William Gooding; Hideho Okada; Theresa L Whiteside
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

8.  Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.

Authors:  Wenjie Chen; Deshen He; Zuyun Li; Xin Zhang; Denghua Pan; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

10.  Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma.

Authors:  Camilla Bjørnbak Holst; Ib Jarle Christensen; Kristoffer Vitting-Seerup; Jane Skjøth-Rasmussen; Petra Hamerlik; Hans Skovgaard Poulsen; Julia Sidenius Johansen
Journal:  Neurooncol Adv       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.